Trial Purpose

The primary objective of this study is to compare belzutifan to everolimus with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR) and to compare everolimus with respect to overall survival (OS). The hypothesis is that belzutifan is superior to everolimus with respect to PFS and OS.

Learn More on ClinicalTrials.gov

CLINICALTRIALS.GOV IDENTIFIER:

NCT04195750

When speaking to your doctor, please have the trial identifier number available.

About The Study

All patients who enroll in the trial will receive medication while on the study.

50% will receive MK-6482

50% will receive everolimus

*Both you and the study doctor will know what study drug you are getting. MK-6482 and everolimus are both tablets that are taken daily by mouth.

Trial Phase Icon

Phase 3

Tests the medicine or vaccine in large groups of trial participants (from several hundred to several thousand). For medicines, volunteers have the disease or condition the medicine is designed to treat. In vaccine studies, the volunteers may be healthy or have diseases or conditions. Phase 3 trials take place in hospitals, clinics, or physician offices.

Trial start Icon

Dates

  • Actual study start date 27 February 2020
  • Estimated primary completion date 17 September 2025
  • Estimated study completion date 17 September 2025

Eligibility

Only a qualified healthcare professional can determine your eligibility. However, this information may be useful in starting a conversation with your doctor.

Conditions Icon

Conditions

Carcinoma, Renal Cell

Age Range Icon

Age Range

18 - No Age Maximum

Sex Icon

Sex

All

Trial locations

Locations provided may not reflect the most current site information. Please call the number provided in the location results to confirm.